Evidence map›Paper›PMID 32107877›Full record

ArticleMolecular genetics & genomic medicine2020

MIR-138-5P inhibits the progression of prostate cancer by targeting FOXC1.

Hui Huang, Ying Xiong, Zhensheng Wu, Yuhui He, Xianglin Gao, Zhangyan Zhou, Tao Wang

Open access · goldAbstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. miR-138-5p inhibits WiT-49 cell growth in vitro by downregulating TCF3 expression, and suppresses tumorigenesis in vivo.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
  3. Article
  4. The Role of miR-138 in Cardiovascular Diseases.BioMed research international · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hui HuangDepartment of Urology, The Affiliated Shunde Hospital of Guangzhou Medical University, Foshan, China.
Ying XiongDepartment of Urology, Yangtze University, Affiliated Hospital 1, Jingzhou, China.
Zhensheng WuDepartment of Urology, The Affiliated Shunde Hospital of Guangzhou Medical University, Foshan, China.
Yuhui HeDepartment of Urology, The Affiliated Shunde Hospital of Guangzhou Medical University, Foshan, China.
Xianglin GaoDepartment of Urology, The Affiliated Shunde Hospital of Guangzhou Medical University, Foshan, China.
Zhangyan ZhouDepartment of Urology, Yangtze University, Affiliated Hospital 1, Jingzhou, China.
Tao WangDepartment of Urology, The Affiliated Shunde Hospital of Guangzhou Medical University, Foshan, China.ORCID 0000-0003-2053-0722
The First People's Hospital of Shunde · CNYangtze University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies have suggested that micro-RNAs (miRNAs) can function as an oncogene or a tumor suppressor in cancers. However, the role of MIR-138-5P (613394) in prostate cancer (PCa) remains unclear.

methodsExpression level of MIR-138-5P in PCa cell lines and normal cell line was analyzed with the quantitative real-time PCR method. Cell counting kit-8 assay, colony formation assay, wound-healing assay, and transwell invasion assay were performed to analyze the biological functions of MIR-138-5P.

resultsWe showed MIR-138-5P expression level was significantly decreased in PCa cell lines compared with the normal cell line. Overexpression of MIR-138-5P inhibits PCa cell proliferation, colony formation, cell migration, and cell invasion in vitro. Mechanistically, we showed Forkhead box C1 (FOXC1, 601090) was a direct target for MIR-138-5P in PCa. We confirmed that overexpression of FOXC1 partially reversed the effects of MIR-138-5P on PCa cell behaviors.

conclusionsCollectively, we showed that MIR-138-5P functions as a tumor suppressor gene in PCa via targeting FOXC1.

Indexed as

Cell Line, TumorCell MovementCell ProliferationForkhead Transcription FactorsGene Expression Regulation, NeoplasticHumansMaleMicroRNAsProstatic NeoplasmsUp-RegulationForkhead Transcription FactorsFOXC1 protein, humanMicroRNAsMIRN138 microRNA, humanFOXC1MIR-138-5Pprostate cancertumor suppressor gene

Identifiers

PMID32107877
PMCPMC7196466
OpenAlexW3008732258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.